Bioharvest Sciences Inc 6-K, filed Nov 18, 2024
Bioharvest Sciences Inc. (BHST)
About this 6-K
Bioharvest Sciences Inc filed this 6-K on November 18, 2024.
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission file number: 000-56663
BIOHARVEST SCIENCES INC.
(Exact name of Registrant as specified in its charter)
Not applicable
(Translation of Registrant’s name into English)
1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
|
Exhibits:
Exhibit | Description |
News Release dated November 15, 2024 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOHARVEST SCIENCES INC. |
| (Registrant) |
|
|
Date: November 15, 2024 | /s/ David Ryan |
| Name: David Ryan |
| Title: Vice-President, Investor Relations & Secretary |
NR: 111524-1 |
| CSE:BHSC – FSE:8MV –NASDAQ:BHST |
BIOHARVEST SCIENCES INC. ANNOUNCES GRANT OF RESTRICTED SHARE UNITS AND STOCK OPTIONS |
VANCOUVER, CANADA, and REHOVOT, ISRAEL, November 15, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV) announces that it has granted 5,400 Restricted Share Units (“RSUs”) to an employee, with a deemed issuance price of CAD $8.48 per share unit. The RSUs will vest after 12 months.
Additionally, the Company has granted 111,998 stock options to consultants and employees. These options are exercisable for common shares of the Company at a price of CAD $8.48 per share, subject to the following vesting terms:
Stock Options Granted | Vesting Terms | Expiring Terms |
4,430 | Vesting quarterly over a 1-year period | 10 Years |
5,428 | Vesting quarterly over a 2-year period | 10 Years |
102,140 | Vesting quarterly over a 3-year period | 10 Years |
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) (NASDAQ: BHST) is a leader in botanical synthesis, leveraging its patented technology process to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Ilan Sobel
Chief Executive Officer
Corporate Contact:
Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622 -1186
Email: info@bioharvest.com
Investor Relations Contact:
MZ Group - MZ North America (949) 259-4987
BHSC@mzgroup.us
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts, and there is no assurance that signed agreements will progress past the first stage. Readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. The Company does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures which can be found under the Company’s profile on www.sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.